MCID: PDT014
MIFTS: 30

Pediatric Ependymoma

Categories: Bone diseases, Cancer diseases, Genetic diseases, Neuronal diseases

Aliases & Classifications for Pediatric Ependymoma

MalaCards integrated aliases for Pediatric Ependymoma:

Name: Pediatric Ependymoma 12 15
Childhood Ependymoma 12
Familial Ependymoma 70

Classifications:



External Ids:

Disease Ontology 12 DOID:5509
NCIt 50 C8578
UMLS 70 C1851584

Summaries for Pediatric Ependymoma

MalaCards based summary : Pediatric Ependymoma, also known as childhood ependymoma, is related to cellular ependymoma and benign ependymoma. An important gene associated with Pediatric Ependymoma is IPO7 (Importin 7). The drugs Methotrexate and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and liver, and related phenotype is Increased proliferation.

Wikipedia : 73 Pediatric ependymomas are similar in nature to the adult form of ependymoma in that they are thought to... more...

Related Diseases for Pediatric Ependymoma

Diseases related to Pediatric Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)
# Related Disease Score Top Affiliating Genes
1 cellular ependymoma 30.6 ZFTA RELA NF2 MEN1
2 benign ependymoma 30.6 ZFTA NF2
3 supratentorial ependymoma 30.2 ZFTA RELA
4 anaplastic ependymoma 29.6 RELA NF2
5 rela fusion-positive ependymoma 10.2 ZFTA RELA
6 keloid formation 10.2 MIR124-3 ASAH1
7 pediatric supratentorial ependymoma 10.1 ZFTA RELA
8 papillary ependymoma 10.0 NF2 MEN1
9 clear cell ependymoma 9.9 ZFTA NF2 MEN1
10 spinal cord glioma 9.9 ZFTA NF2
11 myxopapillary ependymoma 9.8 ZFTA RELA NF2
12 spinal cancer 9.8 ZFTA NF2
13 low grade glioma 9.8
14 hydrocephalus 9.8
15 brain cancer 9.8
16 high grade glioma 9.8
17 myelitis 9.8
18 cranial nerve palsy 9.8
19 pediatric infratentorial ependymoma 9.8
20 chromosomal triplication 9.8
21 glioma 9.8
22 mollaret meningitis 9.8
23 glial tumor 9.8
24 rare tumor 9.8
25 glioma susceptibility 1 9.8
26 paroxysmal extreme pain disorder 9.8
27 triiodothyronine receptor auxiliary protein 9.8
28 meningioma, familial 9.8
29 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
30 familial adenomatous polyposis 9.8
31 intracranial meningioma 9.8
32 tic disorder 9.8
33 secretory meningioma 9.8
34 lymphoplasmacyte-rich meningioma 9.8
35 alopecia 9.8
36 47,xyy 9.8
37 hypoxia 9.8
38 spinal cord ependymoma 9.8 ZFTA NF2 NELL2 MEN1
39 tanycytic ependymoma 9.8 ZFTA RELA NF2 MEN1
40 cerebral ventricle cancer 9.6 ZFTA RELA NF2 NELL2 CBY1
41 cerebrum cancer 9.6 ZFTA RELA NF2 NELL2 CBY1
42 supratentorial cancer 9.6 ZFTA RELA NF2 NELL2 CBY1
43 high grade ependymoma 8.7 ZFTA VILL SEC61G SCHIP1 RELA NF2

Graphical network of the top 20 diseases related to Pediatric Ependymoma:



Diseases related to Pediatric Ependymoma

Symptoms & Phenotypes for Pediatric Ependymoma

GenomeRNAi Phenotypes related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 MEN1 NF2

Drugs & Therapeutics for Pediatric Ependymoma

Drugs for Pediatric Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
2
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
3
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
4
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
5
Valproic acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
6
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
7
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
9 Neurotransmitter Agents Phase 2, Phase 3
10 Psychotropic Drugs Phase 2, Phase 3
11 Tubulin Modulators Phase 2, Phase 3
12 Antirheumatic Agents Phase 2, Phase 3
13 Folic Acid Antagonists Phase 2, Phase 3
14 Vitamin B9 Phase 2, Phase 3
15 Antimitotic Agents Phase 2, Phase 3
16 Folate Phase 2, Phase 3
17 Vitamin B Complex Phase 2, Phase 3
18 Alkylating Agents Phase 2, Phase 3
19 Anticonvulsants Phase 2, Phase 3
20 Antimetabolites Phase 2, Phase 3
21 Dermatologic Agents Phase 2, Phase 3
22
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
23
Etoposide Approved Phase 2 33419-42-0 36462
24 Immunologic Factors Phase 2
25 Immunosuppressive Agents Phase 2
26 Etoposide phosphate Phase 2
27
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
28 Protein Kinase Inhibitors Phase 2
29
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
30
Liposomal doxorubicin Phase 1 31703
31 Antibiotics, Antitubercular Phase 1
32 Liver Extracts Phase 1
33 Anti-Bacterial Agents Phase 1
34
Povidone Approved 9003-39-8 131751496
35
Hyaluronic acid Approved, Vet_approved 9004-61-9 53477741
36
Donepezil Approved Early Phase 1 120014-06-4 3152
37 Adjuvants, Immunologic
38 Viscosupplements
39 Plasma Substitutes
40 Protective Agents
41 Blood Substitutes
42 Hormones
43 Cholinesterase Inhibitors Early Phase 1
44 Cholinergic Agents Early Phase 1
45 Nootropic Agents Early Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
2 SIOP Study of Combined Modality Treatment in Childhood Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
3 Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma Active, not recruiting NCT02155920 Phase 2 Everolimus
4 A Randomized, Phase 2 Study of Single-agent Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma Terminated NCT01032070 Phase 2 erlotinib;etoposide
5 Open-label Phase 2 Study of Single-agent Erlotinib for Patients With Pediatric Ependymoma Previously Treated With Oral Etoposide in Protocol OSI-774-205 Terminated NCT01247922 Phase 2 Erlotinib
6 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
7 Efficacy of Gelclair™ in Reducing the Pain of Oral Mucositis in Children and Young People With Cancer (SC 2005 07) Unknown status NCT00349024 polyvinylpyrrolidone-sodium hyaluronate gel
8 Metabolic Syndrome in Childhood Cancer Survivors Completed NCT00920738
9 A Pilot Study of Donepezil Hydrochloride in Pediatric Brain Tumor Survivors After Cranial Irradiation Completed NCT00452868 Early Phase 1 Donepezil
10 Pilot Study of Early Enteral Tube Feedings in Children Receiving Chemotherapy for Newly Diagnosed AML/MDS and High Risk Solid Tumors Withdrawn NCT00624962

Search NIH Clinical Center for Pediatric Ependymoma

Genetic Tests for Pediatric Ependymoma

Anatomical Context for Pediatric Ependymoma

MalaCards organs/tissues related to Pediatric Ependymoma:

40
Spinal Cord, Brain, Liver

Publications for Pediatric Ependymoma

Articles related to Pediatric Ependymoma:

(show top 50) (show all 77)
# Title Authors PMID Year
1
Bioinformatics analysis of microarray data reveals epithelial-mesenchymal-transition in pediatric ependymoma. 61
33595943 2021
2
The BET Inhibitor OTX015 Exhibits In Vitro and In Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models. 61
33668642 2021
3
Clinical outcomes in a large pediatric cohort of patients with ependymoma treated with proton radiotherapy. 61
32514542 2021
4
Proton Therapy for Pediatric Ependymoma: Mature Results From a Bicentric Study. 61
33508372 2021
5
Pediatric ependymoma: A single-center experience from a developing country. 61
33402598 2020
6
Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas. 61
33271970 2020
7
Surveillance imaging in pediatric ependymoma. 61
32743915 2020
8
Survival after therapy for pediatric ependymoma in a tertiary care center in Saudi Arabia. 61
33307736 2020
9
A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups. 61
32614133 2020
10
Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. 61
32663469 2020
11
Into Thin Air: Hypoxia Drives Metabolic and Epigenomic Deregulation of Lethal Pediatric Ependymoma. 61
32693052 2020
12
CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models. 61
32708733 2020
13
Ependymoma Pediatric Brain Tumor Protein Fingerprinting by Integrated Mass Spectrometry Platforms: A Pilot Investigation. 61
32183175 2020
14
Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma. 61
31276586 2019
15
Pediatric ependymoma: GNAO1, ASAH1, IMMT and IPO7 protein expression and 5-year prognosis correlation. 61
31505435 2019
16
3D extracellular matrix microenvironment in bioengineered tissue models of primary pediatric and adult brain tumors. 61
31586101 2019
17
A systematic review and meta-analysis of outcomes in pediatric, recurrent ependymoma. 61
31502040 2019
18
Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. 61
30811284 2019
19
Feasibility of Dose Escalation in Patients With Intracranial Pediatric Ependymoma. 61
31293971 2019
20
Pediatric ependymoma: current treatment and newer therapeutic insights. 61
30418040 2018
21
Limitations of current in vitro models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. 61
30559935 2018
22
Second cancer risk after radiation therapy of ependymoma using the flattening filter free irradiation mode of a linear accelerator. 61
30125453 2018
23
Radical, Staged Approach to Extensive Posterior Fossa Pediatric Ependymoma: 3-Dimensional Operative Video. 61
29029279 2018
24
Outcomes following proton therapy for pediatric ependymoma. 61
29239262 2018
25
Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. 61
29350470 2018
26
Establishment of primary cell culture and an intracranial xenograft model of pediatric ependymoma: a prospect for therapy development and understanding of tumor biology. 61
29774098 2018
27
Imaging biomarkers of outcome after radiotherapy for pediatric ependymoma. 61
29500084 2018
28
Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. 61
29229328 2018
29
Treatment challenges and outcomes for pediatric intracranial ependymoma at a single institution in Iran. 61
29565756 2018
30
The Pediatric Ependymoma Protein Database (PEPD). 61
29124086 2017
31
Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. 61
28371821 2017
32
Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. 61
28437838 2017
33
Silencing of DNA repair sensitizes pediatric brain tumor cells to γ-irradiation using gold nanoparticles. 61
28501783 2017
34
Pediatric Ependymoma: A Proteomics Perspective. 61
28387652 2017
35
Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. 61
27863964 2016
36
The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. 61
27966655 2016
37
Pediatric Ependymoma. 61
26503805 2016
38
Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. 61
27287856 2016
39
Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma. 61
27104090 2016
40
Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey. 61
27386327 2016
41
Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma. 61
27390862 2016
42
Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling. 61
26500028 2015
43
A common polymorphism in the 5' UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy. 61
26338418 2015
44
Proton beam therapy for pediatric ependymoma. 61
25754294 2015
45
Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. 61
25724157 2015
46
Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors. 61
25486598 2015
47
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. 61
25120190 2014
48
Emotional and behavioral functioning after conformal radiation therapy for pediatric ependymoma. 61
24462384 2014
49
PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival. 61
24077346 2013
50
Endoscopic endonasal transclival approach to a ventral pontine pediatric ependymoma. 61
23992235 2013

Variations for Pediatric Ependymoma

Expression for Pediatric Ependymoma

Search GEO for disease gene expression data for Pediatric Ependymoma.

Pathways for Pediatric Ependymoma

GO Terms for Pediatric Ependymoma

Cellular components related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 ZWINT VILL TP53INP1 SCHIP1 RELA NF2

Biological processes related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.02 ZFTA RELA MEN1 CBY1 ASAH1
2 response to morphine GO:0043278 8.96 RELA GNAO1

Molecular functions related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein N-terminus binding GO:0047485 8.92 ZWINT RELA MEN1 ERCC5

Sources for Pediatric Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....